No Major Effect of Innate Immune Genetics on Acute Kidney Rejection in the First 2 Weeks Post-Transplantation
BackgroundInnate immunity contributes to acute rejection after kidney transplantation. Genetic polymorphisms affecting innate immunity may therefore influence patients’ risk of rejection. IL2 -330T > G, IL10 -1082G > A, -819C > T, and -592C > A, and TNF -308G > A a...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-02-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2019.01686/full |
id |
doaj-09f5dab800634c7eb84f26678c393ba0 |
---|---|
record_format |
Article |
spelling |
doaj-09f5dab800634c7eb84f26678c393ba02020-11-25T00:18:41ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122020-02-011010.3389/fphar.2019.01686504610No Major Effect of Innate Immune Genetics on Acute Kidney Rejection in the First 2 Weeks Post-TransplantationRong Hu0Daniel T. Barratt1Janet K. Coller2Benedetta C. Sallustio3Benedetta C. Sallustio4Andrew A. Somogyi5Andrew A. Somogyi6Discipline of Pharmacology, Adelaide Medical School, University of Adelaide, Adelaide, SA, AustraliaDiscipline of Pharmacology, Adelaide Medical School, University of Adelaide, Adelaide, SA, AustraliaDiscipline of Pharmacology, Adelaide Medical School, University of Adelaide, Adelaide, SA, AustraliaDiscipline of Pharmacology, Adelaide Medical School, University of Adelaide, Adelaide, SA, AustraliaDepartment of Clinical Pharmacology, The Queen Elizabeth Hospital, Adelaide, SA, AustraliaDiscipline of Pharmacology, Adelaide Medical School, University of Adelaide, Adelaide, SA, AustraliaDepartment of Clinical Pharmacology, Royal Adelaide Hospital, Adelaide, SA, AustraliaBackgroundInnate immunity contributes to acute rejection after kidney transplantation. Genetic polymorphisms affecting innate immunity may therefore influence patients’ risk of rejection. IL2 -330T > G, IL10 -1082G > A, -819C > T, and -592C > A, and TNF -308G > A are not associated with acute rejection incidence in Caucasian kidney transplant recipients receiving a calcineurin inhibitor, ciclosporin or tacrolimus (TAC). However, other important innate immune genetic polymorphisms have not yet been extensively studied in recipients and donors. In addition, innate immunogenetics have not been investigated in kidney transplant cohorts receiving only TAC as the calcineurin inhibitor.ObjectiveTo investigate the effect of recipient and donor CASP1, CRP, IL1B, IL2, IL6, IL6R, IL10, MYD88, TGFB, TLR2, TLR4, and TNF genetics on acute kidney rejection in the first 2 weeks post-transplant in TAC-treated kidney transplant recipients.MethodsThis study included 154 kidney transplant recipients and 81 donors successfully genotyped for 17 polymorphisms in these genes. All recipients were under triple immunosuppressant therapy of TAC, mycophenolate mofetil, and prednisolone. Recipient and donor genotype differences in acute rejection incidence within the first 2 weeks post-transplantation were assessed by logistic regression, adjusting for induction therapy, human leukocyte antigen mismatches, kidney transplant number, living donor, and peak panel-reactive antibody scores.ResultsA trend (Cochran-Armitage P = 0.031) of increasing acute rejection incidence was observed from recipient IL6 -6331 T/T (18%) to T/C (25%) to C/C (46%) genotype [C/C versus T/T odds ratio (95% confidence interval) = 6.6 (1.7 to 25.8) (point-wise P = 0.017)]. However, no genotype differences were significant after Bonferroni correction for multiple comparisons.ConclusionsThis study did not detect any statistically significant effects of recipient or donor innate immune genetics on acute rejection incidence in the first 2 weeks post-transplantation. However, the sample size was small, and future larger studies or meta-analyses are required to demonstrate conclusively if innate immune genetics such as IL6 influence the risk of acute rejection after kidney transplantation.https://www.frontiersin.org/article/10.3389/fphar.2019.01686/fulltacrolimusimmune geneticskidney transplantationacute rejectionIL6 -6331 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Rong Hu Daniel T. Barratt Janet K. Coller Benedetta C. Sallustio Benedetta C. Sallustio Andrew A. Somogyi Andrew A. Somogyi |
spellingShingle |
Rong Hu Daniel T. Barratt Janet K. Coller Benedetta C. Sallustio Benedetta C. Sallustio Andrew A. Somogyi Andrew A. Somogyi No Major Effect of Innate Immune Genetics on Acute Kidney Rejection in the First 2 Weeks Post-Transplantation Frontiers in Pharmacology tacrolimus immune genetics kidney transplantation acute rejection IL6 -6331 |
author_facet |
Rong Hu Daniel T. Barratt Janet K. Coller Benedetta C. Sallustio Benedetta C. Sallustio Andrew A. Somogyi Andrew A. Somogyi |
author_sort |
Rong Hu |
title |
No Major Effect of Innate Immune Genetics on Acute Kidney Rejection in the First 2 Weeks Post-Transplantation |
title_short |
No Major Effect of Innate Immune Genetics on Acute Kidney Rejection in the First 2 Weeks Post-Transplantation |
title_full |
No Major Effect of Innate Immune Genetics on Acute Kidney Rejection in the First 2 Weeks Post-Transplantation |
title_fullStr |
No Major Effect of Innate Immune Genetics on Acute Kidney Rejection in the First 2 Weeks Post-Transplantation |
title_full_unstemmed |
No Major Effect of Innate Immune Genetics on Acute Kidney Rejection in the First 2 Weeks Post-Transplantation |
title_sort |
no major effect of innate immune genetics on acute kidney rejection in the first 2 weeks post-transplantation |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Pharmacology |
issn |
1663-9812 |
publishDate |
2020-02-01 |
description |
BackgroundInnate immunity contributes to acute rejection after kidney transplantation. Genetic polymorphisms affecting innate immunity may therefore influence patients’ risk of rejection. IL2 -330T > G, IL10 -1082G > A, -819C > T, and -592C > A, and TNF -308G > A are not associated with acute rejection incidence in Caucasian kidney transplant recipients receiving a calcineurin inhibitor, ciclosporin or tacrolimus (TAC). However, other important innate immune genetic polymorphisms have not yet been extensively studied in recipients and donors. In addition, innate immunogenetics have not been investigated in kidney transplant cohorts receiving only TAC as the calcineurin inhibitor.ObjectiveTo investigate the effect of recipient and donor CASP1, CRP, IL1B, IL2, IL6, IL6R, IL10, MYD88, TGFB, TLR2, TLR4, and TNF genetics on acute kidney rejection in the first 2 weeks post-transplant in TAC-treated kidney transplant recipients.MethodsThis study included 154 kidney transplant recipients and 81 donors successfully genotyped for 17 polymorphisms in these genes. All recipients were under triple immunosuppressant therapy of TAC, mycophenolate mofetil, and prednisolone. Recipient and donor genotype differences in acute rejection incidence within the first 2 weeks post-transplantation were assessed by logistic regression, adjusting for induction therapy, human leukocyte antigen mismatches, kidney transplant number, living donor, and peak panel-reactive antibody scores.ResultsA trend (Cochran-Armitage P = 0.031) of increasing acute rejection incidence was observed from recipient IL6 -6331 T/T (18%) to T/C (25%) to C/C (46%) genotype [C/C versus T/T odds ratio (95% confidence interval) = 6.6 (1.7 to 25.8) (point-wise P = 0.017)]. However, no genotype differences were significant after Bonferroni correction for multiple comparisons.ConclusionsThis study did not detect any statistically significant effects of recipient or donor innate immune genetics on acute rejection incidence in the first 2 weeks post-transplantation. However, the sample size was small, and future larger studies or meta-analyses are required to demonstrate conclusively if innate immune genetics such as IL6 influence the risk of acute rejection after kidney transplantation. |
topic |
tacrolimus immune genetics kidney transplantation acute rejection IL6 -6331 |
url |
https://www.frontiersin.org/article/10.3389/fphar.2019.01686/full |
work_keys_str_mv |
AT ronghu nomajoreffectofinnateimmunegeneticsonacutekidneyrejectioninthefirst2weeksposttransplantation AT danieltbarratt nomajoreffectofinnateimmunegeneticsonacutekidneyrejectioninthefirst2weeksposttransplantation AT janetkcoller nomajoreffectofinnateimmunegeneticsonacutekidneyrejectioninthefirst2weeksposttransplantation AT benedettacsallustio nomajoreffectofinnateimmunegeneticsonacutekidneyrejectioninthefirst2weeksposttransplantation AT benedettacsallustio nomajoreffectofinnateimmunegeneticsonacutekidneyrejectioninthefirst2weeksposttransplantation AT andrewasomogyi nomajoreffectofinnateimmunegeneticsonacutekidneyrejectioninthefirst2weeksposttransplantation AT andrewasomogyi nomajoreffectofinnateimmunegeneticsonacutekidneyrejectioninthefirst2weeksposttransplantation |
_version_ |
1725375139763191808 |